Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 5/20 | 0.81 |
| ▸ | MAOB | P27338 | 3/20 | 0.51 |
| ▸ | HTR1A | P08908 | 3/20 | 0.51 |
| ▸ | HTR7 | P34969 | 2/20 | 0.51 |
| ▸ | DRD3 | P35462 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | HRH1 | P35367 | 1/20 | 0.51 |
| ▸ | HTR2B | P41595 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6950324 | 0.89 | ACHE (1.00) | ACHEKMT2A | |
| SCHEMBL14450985 | 0.85 | ACHE (0.57) | ACHEMAOBHTR1AHTR7DRD3 | |
| SCHEMBL29263737 | 0.84 | HPGD (0.59) | ACHEHTR1AHTR7DRD3CYP1A2 | |
| SCHEMBL19834759 | 0.83 | ACHE (0.57) | ACHEHTR1AHTR7DRD3HRH1 | |
| SCHEMBL6775686 | 0.82 | ACHE (0.55) | ACHEHTR1AHTR7DRD3HRH1 | |
| SCHEMBL6957478 | 0.81 | ACHE (0.74) | ACHECYP1A2CYP2C9CYP2C19KMT2A | |
| SCHEMBL5393686 | 0.81 | DRD3 (0.69) | ACHEMAOBHTR1AHTR7DRD3 | |
| Hydrochloric Acid SCHEMBL19834818 | 0.81 | ACHE (0.54) | ACHEMAOBHTR1AHTR7DRD3 | |
| SCHEMBL5475624 | 0.80 | ACHE (0.53) | ACHE | |
| SCHEMBL17117470 | 0.80 | ACHE (0.59) | ACHEHTR1AHTR7DRD3CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2004188-B1 | BENZOIMIDAZOL-2-YL PYRIDINES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-01 | — | — | EP | disclosed |
| US-7589087-B2 | Benzoimidazol-2-yl pyridines as modulators of the histamine H4receptor | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-09-15 | — | — | US | disclosed |
| EP-2004188-A4 | BENZOIMIDAZOL-2-YL PYRIDINES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-22 | — | — | EP | disclosed |
| EP-2004188-A2 | BENZOIMIDAZOL-2-YL PYRIDINES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007117400-A2 | BENZOIMIDAZOL-2-YL PYRIDINES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-18 | — | — | WO | disclosed |
| US-20070232616-A1 | Benzoimidazol-2-yl pyridines as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232616-A1 | Benzoimidazol-2-yl pyridines as modulators of the histamine H4 receptor | HRH4, HRH3, HRH2 | ACHE 2183/4885MAOB 3076/4885HTR1A 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.